Table 5 Demographic and clinical characteristics - grouped by baseline perianal disease
Variable | Total | Patients with perianal disease | Patients without perianal disease | P value |
|---|---|---|---|---|
N (%) | 499 | 144 (28.9%) | 355 (71.1%) | |
Age (years), mean (SD) | 32.3 (11.43) | 28.9 (10.05) | 33.7 (11.67) | < 0.0001 |
Male, n (%) | 348 (69.7%) | 102 (70.8%) | 246 (69.3%) | 0.7348 |
BMI (kg/m2), mean (SD) | 19.10 (3.198) | 19.29 (3.254) | 19.04 (3.182) | 0.5446 |
Age at disease onset (years), mean (SD) | 27.9 (10.63) | 25.3 (9.40) | 29.0 (10.92) | 0.0003 |
Age group at disease onset (years), n (%) | 0.0556 | |||
N | 499 | 144 | 355 | |
≤ 16 | 29 (5.8%) | 7 (4.9%) | 22 (6.2%) | |
17–39 | 401 (80.4%) | 125 (86.8%) | 276 (77.7%) | |
≥ 40 | 69 (13.8%) | 12 (8.3%) | 57 (16.1%) | |
Age at initial definite diagnosis (years), mean (SD) | 30.6 (11.01) | 27.7 (10.02) | 31.8 (11.19) | 0.0001 |
Time from disease onset to initial diagnosis (months), mean (SD) | 32.0 (46.43) | 29.0 (38.54) | 33.2 (49.27) | 0.3672 |
Time from initial diagnosis to enrollment (months), mean (SD) | 20.6 (39.06) | 14.8 (24.97) | 22.9 (43.29) | 0.0345 |
Time from disease onset to enrollment (months), mean (SD) | 52.6 (59.08) | 43.8 (44.55) | 56.2 (63.75) | 0.0341 |
Nicotine use history, n (%) | 0.0188 | |||
N | 442 | 124 | 318 | |
Never used | 382 (86.4%) | 116 (93.5%) | 266 (83.6%) | |
Current user | 36 (8.1%) | 6 (4.8%) | 30 (9.4%) | |
Former user | 24 (5.4%) | 2 (1.6%) | 22 (6.9%) | |
Alcohol use history, n (%) | 0.3203 | |||
N | 443 | 124 | 319 | |
Never used | 401 (90.5%) | 116 (93.5%) | 285 (89.3%) | |
Current user | 22 (5.0%) | 3 (2.4%) | 19 (6.0%) | |
Former user | 20 (4.5%) | 5 (4.0%) | 15 (4.7%) | |
Location, n (%) | < 0.0001 | |||
N | 493 | 143 | 350 | |
L1 | 137 (27.8%) | 23 (16.1%) | 114 (32.6%) | |
L2 | 71 (14.4%) | 14 (9.8%) | 57 (16.3%) | |
L3 | 277 (56.2%) | 105 (73.4%) | 172 (49.1%) | |
L4 | 8 (1.6%) | 1 (0.7%) | 7 (2.0%) | |
Behavior, n (%) | 0.0309 | |||
N | 495 | 144 | 351 | |
B1 | 247 (49.9%) | 84 (58.3%) | 163 (46.4%) | |
B2 | 148 (29.9%) | 32 (22.2%) | 116 (33.0%) | |
B3 | 100 (20.2%) | 28 (19.4%) | 72 (20.5%) | |
Crohn’s disease treatment information at baseline, n (%) | ||||
Immunomodulators | 207 (41.5%) | 64 (44.4%) | 143 (40.7%) | 0.4480 |
Anti-TNF agents | 164 (32.9%) | 60 (41.7%) | 104 (29.6%) | 0.0098 |
Aminosalicylates | 103 (20.6%) | 23 (16.0%) | 80 (22.8%) | 0.0896 |
Steroids | 99 (19.8%) | 24 (16.7%) | 75 (21.4%) | 0.2350 |
Enteral nutrition | 69 (13.8%) | 24 (16.7%) | 45 (12.8%) | 0.2618 |
Antibiotics | 65 (13.0%) | 30 (20.8%) | 35 (10.0%) | 0.0012 |
Anti-tuberculosis | 27 (5.4%) | 11 (7.6%) | 16 (4.6%) | 0.1705 |
Other agentsa | 115 (23.0%) | 40 (27.8%) | 75 (21.4%) | 0.1251 |